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Huntington’s disease (HD) is a late-onset neurodegenerative disorder that is characterized neuropathologi-
cally by the presence of neuropil aggregates and nuclear inclusions. However, the profile of aggregate struc-
tures that are present in the brains of HD patients or of HD mouse models and the relative contribution of
specific aggregate structures to disease pathogenesis is unknown. We have used the Seprion ligand to
develop a highly sensitive enzyme-linked immunosorbent assay (ELISA)-based method for quantifying
aggregated polyglutamine in tissues from HDmouse models. We used a combination of electron microscopy,
atomic force microscopy (AFM) and sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) to investigate the aggregate structures isolated by the ligand. We found that the oligomeric,
proto-fibrillar and fibrillar aggregates extracted from the brains of R6/2 and HdhQ150 knock-in mice were
remarkably similar. Using AFM, we determined that the nanometre globular oligomers isolated from the
brains of both mouse models have dimensions identical to those generated from recombinant huntingtin
exon 1 proteins. Finally, antibodies that detect exon 1 Htt epitopes differentially recognize the ligand-
captured material on SDS–PAGE gels. The Seprion-ligand ELISA provides an assay with good statistical
power for use in preclinical pharmacodynamic therapeutic trials or to assess the effects of the genetic manipu-
lation of potential therapeutic targets on aggregate load. This, together with the ability to identify a spectrum of
aggregate species in HD mouse tissues, will contribute to our understanding of how these structures relate to
the pathogenesis of HD and whether their formation can be manipulated for therapeutic benefit.
INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant
late-onset neurodegenerative disorder with a mean age of
onset of 40 years. Symptoms include psychiatric disturbances,
motor disorders, cognitive decline and weight loss. Disease
duration is 15–20 years and there are no effective disease-
modifying treatments (1). The disease is caused by an
expanded CAG trinucleotide repeat in the HD gene that is
translated into a polyglutamine (polyQ) repeat in the
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huntingtin (Htt) protein (2). Neuropathologically, HD is charac-
terized by a generalized brain atrophy as well as neuronal cell
loss in the striatum, cortex and other brain regions. Intracellular
polyQ-containing aggregates are deposited throughout the neu-
ropil and as inclusions in neuronal nuclei (3,4).
PolyQ aggregates formed in vitro from recombinant protein
comprise a range of oligomeric, proto-fibrillar and fibrillar
structures (5–7). However, it is not known whether these
reflect the oligomeric polyQ structures that form in vivo in
HD patients or in HD mouse models. Similarly, although the
genetic and pharmacological manipulation of polyQ aggregates
in vitro and in invertebrate disease models has suggested that
either the prevention of aggregate formation or their partition
into less toxic structures can have beneficial consequences
(5,8–12), the role that polyQ aggregates play in disease pathol-
ogy remains unclear. The ability to monitor the effects of aggre-
gate manipulation in HD mouse models would help to
determine the relevance of experiments performed in simple
model systems. To this end, it is essential that the aggregate
load in mouse tissues can be quantified and that the aggregate
species that form in vivo can be identified.
We utilized two HD mouse models that were generated by
very different approaches. The R6/2 mouse is transgenic for a
human exon 1 Htt protein which in our colony has approxi-
mately 200Q (13). These mice develop an early-onset pheno-
type with rapid disease progression and as a consequence can
realistically be used as a therapeutic screening tool (14). In our
R6/2 colony, nuclear inclusions can be readily detected by
immunohistochemistry in the cerebral cortex, striatum and
hippocampus by 3 weeks of age (15,16), RotaRod impairment
is apparent by 6 weeks and end-stage disease occurs at 15
weeks. The HdhQ150 knock-in mouse is a more genetically
precise model of the human disease, and carries approximately
150Q which has been inserted into the mouse Hd gene (Hdh)
(17). In our HdhQ150/Q150 colony, nuclear inclusions were
detected by immunohistochemistry in the striatum and hippo-
campus by 6 months and the cortex by 8 months (18), an
impaired RotaRod performance was apparent by 18 months
of age and end-stage disease occurs at around 22 months
(18). The HdhQ150 mice develop a phenotype that is remark-
ably similar to that found in R6/2 except that onset is much
delayed and the disease progresses much more slowly over a
period of 22 months (18,19). At the level of light microscopy,
a complex distribution of aggregates in the form of nuclear
inclusions and cytoplasmic aggregates are widely distributed
throughout the brains of both models (18).
Quantification of the aggregate load in mouse tissues has
primarily involved counting the number of striatal nuclear
inclusions and measuring their diameter. However, this only
samples a subset of the aggregate species in one small brain
region and more quantitative approaches that are less work-
intensive are desperately needed. We have previously used
the filter retardation assay to detect aggregates in mouse
tissues (20) but we have been unsuccessful in optimizing
this as an in vivo screening tool owing to signal variability.
However, even if these technical difficulties were overcome,
this approach would still have the disadvantage of only
measuring the presence of aggregates that are larger than the
cellulose acetate membrane pore size and therefore retained
on the membrane.
Here we describe the use of the Seprion ligand to establish
an enzyme-linked immunosorbent assay (ELISA)-based
method that provides a rapid, highly sensitive assay with
good statistical power to detect changes in aggregate load in
the brains of mouse models of HD. We demonstrate that the
ligand captures a remarkably similar range of oligomeric,
proto-fibrillar and fibrillar aggregates from the brains of both
the R6/2 and HdhQ50 mouse models and that these are com-
parable to those generated from recombinant proteins in vitro.
Using atomic force microscopy (AFM) we show that the
dimensions of nanometre globular aggregates from the R6/2
and HdhQ150 knock-in brains are identical to those generated
by the aggregation of recombinant exon1 Htt proteins contain-
ing just 46 and 53 polyQs. Finally, antibodies that detect exon
1 Htt epitopes differentially recognize the ligand-captured
material on sodium dodecyl sulphate–polyacrylamide gel
electrophoresis (SDS–PAGE) gels.
RESULTS
The Seprion ligand ELISA provides a highly quantitative
assay for measuring polyQ aggregate load in Huntington’s
disease mouse tissue
The Seprion ligand has previously been used to isolate and
quantify aggregated forms of the prion protein, PrpSc
(21,22). It is a high molecular weight polymeric ligand that
consists of repeating charged and hydrophobic chemical
groups that interact with similar repeating groups that occur
on aggregated proteins. The selectivity for aggregated proteins
is based on the arrangement of large numbers of polar and
hydrophobic regions in aggregated proteins which occur to a
much lesser extent in a single unaggregated protein molecule.
We have used the Seprion ligand to develop an ELISA-
based plate assay by which aggregated Htt is captured from
tissue lysates and detected by immunoprobing with the S830
antibody that was raised against the N-terminal exon 1 Htt
protein (23). We quantified the aggregate load in each of the
five brain regions from female R6/2 mice at 2, 4, 6, 8 and
12 weeks of age. The Seprion ligand extracted statistically sig-
nificant levels of aggregates from the striatum and hippo-
campus at 2 weeks of age, the cerebral cortex and brain
stem at 4 weeks and cerebellum at 6 weeks (Fig. 1A). Only
signals corresponding to background levels were measured
in wild-type (WT) samples, equivalent to those obtained
with capture-buffer only controls. The ELISA readings have
proved to be highly reproducible between experiments, e.g.
there was no difference in the aggregate load measured in
the cortex from four different series of 12-week-old R6/2
mice using different batches of ligand-coated plates over a
period of 2 years (F(3,21) ¼ 2.121, P ¼ 0.133). We have pre-
viously shown that nuclear inclusions form in a number of
R6/2 peripheral tissues (24). We applied the Seprion ELISA
to quantify the corresponding aggregate levels and found
that statistically significant amounts could be detected by 8
weeks in muscle and by 12 weeks in pancreas and liver
(Fig. 1B). Therefore, the Seprion ELISA might provide a
highly sensitive method of quantifying the level of aggregated
polyQ in tissues from mouse models of HD. This assay has
great potential for use as an outcome measure either in
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Figure 1. Seprion ligand quantification of aggregate load in tissues from HD mouse models. Quantification of aggregate levels in brain regions (A) and periph-
eral tissues (B) of R6/2 mice. (C) Power analysis indicating the number of R6/2 mice required to have an 80% chance of detecting a specific percentage reduction
in aggregate load in response to a therapeutic intervention initiated at 4 weeks of age and terminated at either 8 weeks or 12 weeks of age (P . 0.05). Quanti-
fication of aggregate levels in brain regions (D) and peripheral tissues (E) of HdhQ150/Q150 mice. In all cases, n ¼ 6/genotype/age and the age at which statisti-
cally significant aggregate levels can first be detected is indicated by the corresponding P-value. Black bars ¼ R6/2 or HdhQ150, gray bars ¼ wild-type. Ctx ¼
cerebral cortex; Hipp ¼ hippocampus; Str ¼ striatum; Cerb ¼ cerebellum; Br St ¼ brain stem; Buf ¼ buffer.
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preclinical efficacy trials to test the effect of potential thera-
peutic interventions or in mice with genetic modifications
that might modulate HD-related mouse phenotypes. For
example, for the purpose of a pharmacodynamic trial in
which a compound has been administered to R6/2 mice from
4 to 8 weeks of age, power calculations (25) indicate that as
few as eight mice would be sufficient to give an 80%
chance of detecting a 30–50% reduction in aggregate load
in brain regions (P, 0.05; Fig. 1C).
The aggregate pathology in the R6/2 mice occurs through-
out the brain and in many peripheral tissues. We had
assumed that this widespread distribution occurred because
they express a small N-terminal fragment of mutant Htt.
Therefore, we were surprised to find that at end-stage
disease, polyQ aggregates in the form of nuclear inclusions
and cytoplasmic aggregates are present in all brain regions
of homozygous HdhQ150/Q150 knock-in mice (18). Similarly,
we have recently demonstrated that the distribution of polyQ
aggregates throughout the peripheral tissues of 12–14 week
R6/2 mice and 22 month HdhQ150 knock-in mice is almost
identical (H. Moffitt, G. McPhail, B. Woodman, C. Hobbs
and G. Bates, manuscript in preparation) suggesting that HD
pathology may not be restricted to the CNS in HD patients.
Therefore, we applied the Seprion ELISA to measure the
level of polyQ aggregation that had accumulated in the cerebral
cortex, hippocampus and brain stem from HdhQ150/Q150 mice
aged 6, 10, 18 and 22 months (Fig. 1D). The striata and cere-
bella from this series of tissues had been used for RNA analyses
(18). As with the R6/2 mice, statistically significant levels were
present in the hippocampus (6 months) before the cortex and
brain stem (10 months). These ages correspond to those at
which inclusions are apparent in the brain by light microscopy
(18). In the periphery, statistically significant levels of aggre-
gates could be detected in muscle and liver at 22 months
(Fig. 1E). The microplate readings were lower for the
HdhQ150/Q150 tissues than for the R6/2 tissues. However, the
difference in these values does not necessary reflect differences
in the levels of aggregates that have accumulated in the tissues
of the two models. The S830 antibody has a different affinity to
the mutated versions of human Htt (in the R6/2 mouse) and
mouse Htt (in the HdhQ150 knock-in mice).
Immuno-EM reveals diverse oligomeric and fibrillar
Htt species in brain tissue from Huntington’s disease
mouse models
We employed immuno-electron microscopy (EM) to investi-
gate the morphology of the ligand-isolated aggregated Htt
species. Aggregates were captured from cortical lysates by
Seprion ligand-coated magnetic beads and eluted onto EM
grids, processed for transmission EM and immunoprobed
with gold-labelled MW8 (26), MW1 (26) or 3B5H10 (27).
Bead capture was performed on cortices from R6/2 mice
aged 2, 4, 6 and 12 weeks and from HdhQ150/Q150 mice aged
2, 3, 4 and 22 months as well as on the cortices of matched
WT littermates at each time point. The number of mice exam-
ined is summarized in Table 1. While in the case of R6/2 mice,
we chose time points that span the course of the disease, for
the HdhQ150/Q150 we instead focussed on young mice, asking
how soon aggregate structures can be detected, but also
included mice at end-stage disease for comparison with late-
stage R6/2. HdhQ150/Q150 mice aged 2, 3 and 4 months
would all correspond to R6/2 mice of less than 4 weeks of
age with respect to the stage of disease.
Immunolabelling of bead captured and eluted cortical
aggregates from both R6/2 and HdhQ150/Q150 cortices with
MW8 consistently identified fibrillar structures. The fibrils
captured from the R6/2 series of tissues increased in both
amount and size as a function of disease progression and
could be detected as early as 2 weeks of age (Fig. 2A). In
the case of the HdhQ150/Q150 knock-in mice, fibrils were pro-
minent at 22 months and were isolated from the cortex of
mice as young as 2 months (Fig. 2B). The antibodies MW1
and 3B5H10 detected a variety of small aggregate structures
including oligomers and protofibrils in both mouse models
(Fig. 2A and B). The complete spectrum of captured aggre-
gate structures, the age of mouse from which each was iso-
lated, and the antibodies with which they were detected is
summarized in Figure 3. The Seprion ligand captured a
range of oligomeric/proto-fibrillar (Fig. 3B–E) and fibrillar
(Fig. 3F–I) structures. Large filamentous aggregates have fre-
quently been generated from polyQ peptides (28,29) and exon
1 Htt proteins (6,7,30,31) in vitro and visualized by EM. In
one case, EM has been used to describe fibrillar structures
purified from the brains of an inducible HD mouse model
by gradient fractionation (32). The filamentous/fibrillar
aggregates isolated by the Seprion ligand (Fig. 3F–I were
in all cases recognized by MW8, but MW1 and 3B5H10 epi-
topes were only present on the smaller, immature fibrils
(Fig. 3F).
The structures illustrated in Figure 3A–E have not previously
been isolated from in vivo tissues. Those shown in panels A–D
were captured from both R6/2 andHdhQ150/Q150 brains, whereas
the proto-fibrillar bundles illustrated in (E) were only observed
in material extracted from HdhQ150/Q150 knock-in mice. The
immunolabelled shadows depicted in Figure 3A were captured
from R6/2 and HdhQ150/Q150brains, were detected with both
MW1 and 3B5H10 and never seen in the material captured
from WT mice. However, whether they represent an aggregated
form of the protein is not clear. The structures shown in
Figure 3B and C have been formed by in vitro aggregation of
44Q exon 1 Htt (6), of a truncated 30Q exon 1 protein (7),
polyQ peptides (28) and of Ab42 (30) and termed oligomers
(6,30) and oligomers/protofibrils (7). Those illustrated in
Figure 3D and E have been generated in vitro from 44Q exon
1 Htt (6), and the truncated 30Q exon 1 protein (7) and termed
oligomers and protofibrils. We used electron tomography to
reveal the three-dimensional structure of the protofibrillar
bundles in Figure 3D (Fig. 4A) and the thin filaments in
Figure 3G (Fig. 4B). Figure 4 presents still images of the
Table 1. Number of R6/2 and wild-type (WT) mice used for the electron
microscopy and SDS–PAGE analyses
Age (weeks) R6/2 WT Age (months) HdhQ150/Q150 WT
2 8 4 j 2 3 14 8 4 3 2 16 7 3 4 2 1
12 11 6 22 2 1
68 Human Molecular Genetics, 2010, Vol. 19, No. 1
three-dimensional structures shown in the movies in Sup-
plementary Material, Figure S1.
Globular nanometre oligomers isolated from the R6/2 and
HdhQ150/Q150 mouse brains have identical dimensions as
those generated from exon 1 Htt proteins in vitro
We applied AFM to provide a more quantitative comparison
of the oligomeric aggregates that were captured by the
Seprion ligand. We discovered empirically that elution with
100 mM KCl (as described in the Materials and Methods) dif-
ferentially eluted globular nanometre oligomers, while other
aggregate species remained bound to the ligand. We used
western blotting to demonstrate that the eluted material was
an oligomeric form of Htt (Supplementary Material,
Figure S2). The globular oligomers appeared to be very
similar to those that had been previously generated in vitro
(5,6,31) and, therefore, we focussed our AFM analysis on
the quantification of these structures rather than on fibrillar
structures which we had identified and characterized exten-
sively by EM (Figures 2 and 3). Globular oligomers were cap-
tured from cortical tissue from R6/2 mice aged 2, 4, 6 and 12
weeks (n ¼ 2/per age), from HdhQ150/Q150 aged 2, 3, 8 and 22
months (n ¼ 2/age) and from matched WT controls. Particles
of approximately 20–40 nm in diameter were eluted from
ligand-coated beads from both R6/2 and HdhQ150/Q150 brains
Figure 2. Immuno-EM analysis of captured material from R6/2 and HdhQ150/Q150 cortex. Representative examples of immunogold labelling of Htt aggregates
with MW8, MW1 and 3B5H10 captured from the cortex of (A) R6/2 mice aged 2 and 12 weeks of age and (B) HdhQ150/Q150 mice aged 2 and 22 months of age.
MW8 immunolabels fibrillar structures at each age in both the R6/2 and HdhQ150/Q150 tissue. Oligomers and protofibrils (A) and oligomers (B) detected by MW1
and protofibrils (A) and oligomers (B) detected by 3B5H10 are shown. Scale bar ¼ 100 nm.
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Figure 3. Variation in the oligomeric and fibrillar structures isolated from R6/2 and HdhQ150/Q150 brains before phenotype onset and at late-stage disease. (A)
Immunolabelled ‘shadows’, (B–E) oligomeric/proto-fibrillar structures and (F–I) immature fibrils and fibrillar structures that have been consistently captured by
the Seprion ligand bead-captured material as identified by transmission EM and immunogold-labelling. The right-hand table indicates the age at which a structure
was identified in each of the mouse models and if present, whether it was associated with immunogold labelling with MW1, 3B5H10 or MW8. Scale bar ¼
100 nm.
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at all ages tested (Fig. 5A). No oligomeric structures were
eluted from WT tissue. For comparison, oligomers were gen-
erated in vitro by the aggregation of 2 mM recombinant exon 1
Htt proteins with either 53Q or 46Q for 1 h (Fig. 5A). It was
striking that the dimensions of the globular oligomers that
were eluted from ligand-captured material from both R6/2
and HdhQ150/Q150 tissue was found to be identical to those gen-
erated from the incubation of the recombinant exon 1 Htt pro-
teins in vitro (Fig. 5B).
The Seprion ligand captures Htt species that resolve as
monomers on SDS–PAGE
We employed SDS–PAGE to investigate the detergent-soluble
properties of the mutant Htt species that were eluted from the
Seprion ligand after capture from cortical lysates using ligand-
coated magnetic beads. Eluted material from R6/2 mice aged 2,
4, 6 and 12 weeks of age was fractionated by SDS–PAGE
alongside age-matched tissue lysates and immunoprobed with
a series of antibodies: S830, MW1, MW8 and 3B5H10
(Fig. 6). In tissue lysates, all four antibodies detected the
soluble R6/2 transprotein monomer that became less intense
with age because of its sequestration into polyQ aggregates.
The migration of the transprotein varied between lysates
because the CAG repeat is unstable on transmission and there-
fore the polyQ repeat length differed between mice. Although
an exon 1 Htt protein that carries a polyQ repeat of approxi-
mately 200Q is approximately 30 kDa in size, its migration
by SDS–PAGE was retarded to approximately 80 kDa by the
polyQ tract. Both S830 and 3B5H10 (Fig. 6A, D, E and F),
and in some cases MW1 (Fig. 6C), detected a high molecular
weight fragment in cortical lysates that migrated at the top of
the resolving gel and rapidly diminished with age (as indicated
by asterisk). MW1 detected the soluble transprotein in 4 and 6
week lysates and at 12 weeks, in most experiments, it detected a
doublet above which there is a smear overlaying a ladder of
fragments (Fig. 6G). From 6 weeks of age onwards, S830 and
MW8 (Fig. 6A and B), but not MW1 or 3B5H10, detected
detergent-insoluble aggregates that were retained in the stack-
ing gel.
After bead-capture and SDS–PAGE, S830 and MW8 only
detected the detergent-insoluble aggregates in the stacking
gel, indicating that the soluble protein had not been extracted
by the Seprion ligand (Fig. 6A and B). In contrast, MW1 and
3B5H10 detected fragments in the bead-captured material that
resolved at a similar size to the soluble transprotein, but that
were not detected by either S830 or MW8 (Fig. 6C–G). In
material captured from the same lysates, MW1 and 3B5H10
produced comparable signals on western blots (Fig. 6C–E).
The signals obtained with MW1 were always prominent in
lysates from 4-week-old mice (.15 separate experiments).
However, the ligand captured Htt species that resolve as a
soluble monomer were not only seen at younger ages and
were also captured from lysates of 6, 8 or 12 week R6/2
mice as detected by 3B5H10 (Fig. 6F). These fragments
were never detected with S830 or MW8. The consistency of
the MW1 results make it unlikely that an interaction
between soluble exon 1 Htt and the ligand is causing the
exon 1 protein to adopt a structure (retained upon SDS–
PAGE), as if that were the case, there would be no reason to
expect their detection to be disease-stage specific. Instead,
the Seprion ligand has extracted either aggregated Htt
species or misfolded monomers, which upon SDS–PAGE
exhibited a comparable migration to that of the soluble
monomer but are differentially recognized by antibodies that
detect the exon 1 Htt protein.
DISCUSSION
We have shown that the Seprion ligand can be used to isolate and
characterize aggregated Htt species that form in mouse models
of HD. Using EM and AFM we have demonstrated that the
brains of both the R6/2 and HdhQ150 knock-in mouse models
contain a diverse and comparable range of Htt aggregate struc-
tures. The oligomeric and fibrillar aggregates that were captured
by the Seprion ligand were remarkably similar to those that have
previously been generated through the aggregation of exon 1 Htt
proteins in vitro (5,7,33,34). This similarity was particularly
striking in the case of our AFM analysis where the dimensions
of the nanometre globular oligomers isolated from the R6/2
and HdhQ150/Q150 brains were practically identical to those gen-
erated from recombinant exon 1 Htt in vitro. This finding was
unexpected given that HdhQ150 knock-in mice express full-
length mouse Htt with approximately 150Q, R6/2 mice
Figure 4. Still images of the electron tomography of oligomeric/proto-fibrillar structures captured from R6/2 and HdhQ150/Q150 brains for which the three-
dimensional structure is shown in Supplementary Material, Figure S1. (A) Electron tomography of oligomeric structures illustrated in Figure 3D and B of
the filamentous structures illustrated in Figure 3G immunolabelled with MW8.
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Figure 5. AFM analysis of nanometre globular aggregates from R6/2 and HdhQ150/Q150 brains. (A) AFM of Seprion ligand-captured material from both R6/2 and
HdhQ150/Q150 cortex at the ages indicated fractionated to resolve nanometre globular oligomers. Observed aggregates were similar to those generated by the in
vitro incubation of exon 1 Htt proteins with 53Q or 46Q at 2 mM for 1 h. Scale bar ¼ 400 nm. (B) Histograms collating the height, diameter, volume and aspect
ratio (longest width/shortest width) of the R6/2 and HdhQ150/Q150 aggregates measured at all ages. There is a remarkable similarity in the dimensions of the
aggregates isolated from the R6/2 and HdhQ150/Q150 mice. These are comparable to those generated by the aggregation of 2 mM exon 1 Htt proteins with
53Q or 46Q in vitro for 1 h.
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Figure 6. SDS–PAGE and immunoblotting of Seprion bead-captured aggregates from R6/2 cortex. Seprion ligand bead-captured material was fractionated by
10% SDS–PAGE alongside the corresponding mouse lysates. Blots were immunoprobed with S830 (A), MW8 (B), MW1 (C,G) or 3B5H10 (D–F) antibodies.
In (C) and (D) material had been captured from the same lysates, fractionated on two gels and subsequently immunoprobed with MW1 (C) and 3B5H10 (D). The
blot in (C) was stripped and reprobed with 3B5H10 (F). Asterisks denote high molecular bands detected by S830, 3B5H10 and MW1 that enter the resolving gel.
Arrows indicate fragments that resolve at a size similar to monomeric Htt that are differentially recognized by the Htt antibodies. T ¼ R6/2 transgenic; Wt ¼
wild-type; B ¼ buffer; W ¼ well; In ¼ interface between the stacking and resolving gel.
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express a human exon 1 Htt transgene with approximately 200Q
and the recombinant proteins were human exon 1 Htt with 46Q
and 53Q. However, this observation is in keeping with our recent
demonstration that the smallest N-terminal fragment generated
from full-length Htt in the HdhQ150 knock-in mice is an exon
1 Htt protein (C. Landles, K. Sathasivam, A. Weiss,
B. Woodman, H. Moffitt, S. Finkbeiner, B. Sun, J. Gafni,
L. Ellerby, Y. Trottier, W. Richards, A. Osmand, P. Paganetti
and G. Bates, manuscript in preparation), and demonstrates
that the wide variation in polyQ length carried by these exon 1
proteins does not have a detectable impact on the dimensions
of the globular oligomers.
We extracted a diverse spectrum of oligomeric and fibrillar
structures from the brains of both the R6/2 and HdhQ150
mouse models. In the case of R6/2, we analysed brain tissue
from mice aged 2, 4, 6 and 12 weeks of age, spanning the
course of disease from a presymptomatic state to pronounced
symptomatology. The entire spectrum of aggregate species
was extracted from the brain tissue at each of these ages.
However, the amount of fibrillar material increased consider-
ably with disease progression to the extent that the EM grids
were covered in fibrils from R6/2 mice at 12 weeks and
HdhQ150/Q150 mice at 22 months. At late-stage disease the
high density of fibrillar aggregates most likely masked the
presence of oligomeric and proto-fibrillar structures making
it difficult to assess their relative contributions. Our analysis
of HdhQ150/Q150 mice focussed on very early time-points (2,
3 and 4 months), all of which precede overt symptomatology
by several months, as we were interested in determining how
early aggregated structures can be identified in these mice.
Surprisingly, we were able to extract aggregate structures
from HdhQ150/Q150 brains as early as 2 months of age.
Fibrillar aggregates have previously been imaged in tissue
sections from HD post-mortem brains and HD mouse
models (3,15,35) by EM, and therefore, we can be confident
that the fibrillar structures that we have extracted from tissue
sections exist in vivo. However, without being able to image
mutant Htt oligomers and proto-fibrils in tissue sections, we
cannot be certain that the aggregates isolated by the Seprion
ligand have the same structure as those that form in vivo. To
address this, we propose that the complexity of the aggregate
structures that have been isolated, and the consistent variabil-
ity in their relative proportions at different stages of disease,
make it extremely unlikely that they have been generated
through an interaction between the ligand and the soluble
mutant Htt protein. In addition, as well as being very compar-
able to those that have been generated in vitro from exon 1
mutant Htt constructs they are also remarkably similar to
those formed by other amyloidogenic proteins that have
been studied in detail (36–39).
In this study, we used a panel of antibodies that recognize
epitopes within the exon 1 Htt protein: MW8, MW1,
3B5H10 and S830. In all cases, these antibodies recognize a
subset of exon 1 Htt structures. S830 is our in-house sheep
polyclonal antibody that was raised against an exon 1 Htt
recombinant protein with 53Q (23). We routinely use this anti-
body for western blots, on which it detects an exon 1 Htt
monomer and the detergent-insoluble aggregated Htt that is
retained in the stacking gel. We also use S830 for the detection
of intranuclear inclusions and cytoplasmic aggregates by
immunohistochemistry. MW8 also detects both the soluble
exon 1 Htt monomer and detergent-insoluble aggregated
forms on western blots. It is raised against an epitope at the
C-terminus of exon 1 Htt and we have recently shown that
although MW8 can be used to immunoprecipitate full-length
Htt and all N-terminal proteolytic fragments thereof, if used
to probe western blots, it behaves as a C-terminal exon 1
Htt neo-epitope antibody. On western blot, it only detects an
exon 1 Htt protein and does not detect the C-terminus of
exon 1 if it is embedded in a larger fragment of Htt
(C. Landles, K. Sathasivam, A. Weiss, B. Woodman,
H. Moffitt, S. Finkbeiner, B. Sun, J. Gafni, L. Ellerby,
Y. Trottier, W. Richards, A. Osmand, P. Paganetti and
G. Bates, manuscript in preparation). This suggests that MW8
is sensitive to the conformation of this epitope. In this study,
MW8 detected monomeric Htt and detergent-insoluble aggre-
gates on western blots as would be predicted. When immuno-
gold labelled and used for EM, MW8 detected the fibrillar but,
surprisingly, not oligomeric Htt that had been extracted from
R6/2 brains. It would be surprising if the epitope had been
cleaved or processed in oligomers, but not in fibrils and therefore
the failure to detect oligomeric structures is more likely owing to
the fact that the epitope has become inaccessible to MW8 or has
adopted a conformation not recognized by MW8.
The monoclonal antibodies MW1 and 3B5H10 both recog-
nize an expanded polyQ tract. It is known that the MW1
epitope is rapidly lost upon aggregation (10) and MW1 has
been proposed to bind polyQ in a linear lattice model (40).
Consistent with this, we found that MW1 and 3B5H10 did
not recognize the detergent-insoluble aggregated material
that is retained in the stacking gel on western blots and
failed to detect fibrillar structures by immuno-EM. We per-
formed SDS–PAGE and western blot analysis to examine
the detergent solubility of the Seprion ligand material that
had been captured from R6/2 mouse brains at different
stages of disease. We had expected that the captured material
would be retained in the stacking gel as was observed by
immunoprobing with S830 and MW8. Unexpectedly, MW1
and 3B5H10 identified exon 1 Htt fragments with a compar-
able migration to the soluble monomer which were predomi-
nantly detected in lysates of brain tissue from R6/2 mice at
4 weeks of age. Both antibodies recognize the polyQ tract.
A crystal structure of MW1 bound to polyQ showed that
polyQ can adopt an extended coil-like structure (41) and an
independent study demonstrates that 3B5H10 binds to a
compact b-sheet-like structure of polyQ in a monomeric Htt
fragment (M. Arrasate, J. Miller, E. Brooks, C. Peters-Libeu,
J. Legleiter, D. Hatters, J, Curtis, K. Cheung, P. Krtishnan,
S. Mitra, K. Widjaja, B. Shaby, Y. Newhouse, G. Lotz,
V. Thulasiramin, F. Saudou, P. Muchowski, M. Segal,
K. Weisgraber and S. Finkbeiner, manuscript in preparation).
The Seprion ligand appears to extract structures from R6/2
brains that are detergent-soluble and are recognized by
MW1 and 3B5H10 when fractionated by SDS–PAGE. It is
not clear why these fragments are not detected by S830 and
MW8, especially by S830, which gives very strong signals
on western blots of brain lysates.
We have developed a highly quantitative ELISA-based
assay for measuring the aggregate load in tissues from
mouse models of HD with good statistical power. This has
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provided us with a rapid and sensitive pharmacodynamic
read-out for the preclinical assessment of therapeutic
approaches predicted to modify Htt aggregation. This assay
can also be used to determine whether specific genetic manip-
ulations can modify Htt aggregation and other mouse
HD-related phenotypes, thereby facilitating a preclinical vali-
dation of potential therapeutic targets. This can be comple-
mented with agarose gel electrophoresis for resolving
aggregates (AGERA), an agarose gel-based method that has
the potential to detect overall changes in aggregate size distri-
bution (42). Chemical compounds and molecular chaperones
that partition aggregates into less toxic species in vitro have
been identified (5,10,30). Our ability to quantify the aggregate
load in the tissues from HD mouse models and to identify a
range of aggregate structures that form in vivo will be essential
in validating the therapeutic potential of these approaches.
MATERIALS AND METHODS
Huntington’s disease mouse models
Hemizygous R6/2 mice (13) were bred by backcrossing R6/2
males to (CBA  C57Bl/6) F1 females (B6CBAF1/OlaHsd,
Harlan Olac, Bicester, UK). HdhQ150/Q150 homozygous
knock-in mice (17,18) on a (CBA  C57Bl/6) F1 background
were generated by intercrossing HdhQ150/Q7 heterozygous
CBA/Ca and C57BL/6J congenic lines (inbred lines from
Harlan Olac, Bicester, UK). All the animals were subject to
a 12 h light/dark cycle and had unlimited access to water
and breeding chow (Special Diet Services, Witham, UK).
Housing conditions and environmental enrichment were as
previously described (25). R6/2 mice were always housed
with WT mice. The CAG repeat size in the R6/2 mice was
202.6+ 4.7 and in the HdhQ150 mice was 155.8+ 1.0 (SD).
Genotyping and CAG repeat sizing
R6/2 and HdhQ150/Q150 mice were identified by polymerase
chain reaction of tail-tip DNA. For R6/2, a 10 ml reaction con-
tained 100 ng DNA, 1  Thermo-Start master mix (Thermo
Scientific), 1 ml DMSO, 10 ng/ml forward primer 33727
[50-CGCAGGCTAGGGCTGTCAATCATGCT-30] and 10 ng/ml
reverse primer 32252 [50-TCATCAGCTTTTCCAGGGTC
GCCAT-30]. Cycling conditions were: 15 min at 948C, 35 
(30 s at 948C; 30 s at 608C, 60 s at 728C) and 10 min at
728C. The amplified R6/2 transgene product was 272 bp. For
HdhQ150 mice, a 20 ml reaction contained 150 ng tail-tip
DNA, 0.1 mM dNTPs, 2 M betaine (Sigma), 1 Detloff
buffer [15 mM Tris–HCl (pH 8.8), 15 mM Tris–HCl (pH
9.0), 16 mM (NH4)2SO4, 2.5 mM MgCl2, 0.15 mg/ml bovine
serum albumin (BSA), 0.007% b-mercaptoethanol], 10 ng/ml
forward primer MHD16 [50-CCCATTCATTGCCTTGCTGC
TAGG-30], 10 ng/ml reverse primer MHD18 [50-GACTCAC
GGTCGGTGCAGCGGTTCC-30] and 1 U Herculase Taq
polymerase (Stratagene). Amplification conditions were:
5 min at 958C, 30  (30 s at 948C, 30 s at 588C, 3 min at
728C) and 5 min at 728C. The WT allele amplified a 278 bp
product, whereas the HdhQ150 knock-in allele amplified an
approximately 707 bp product. Amplification of the CAG
repeat from R6/2 mouse DNA was performed with a FAM-
labelled forward primer (GAGTCCCTCAAGTCCTTCC
AGCA) and reverse primer (GCCCAAACTCACGGTCGGT)
in 10 ml reactions containing: 0.2 mM dNTPs; 10% DMSO;
AM buffer (67 mM Tris–HCl pH 8.8; 16.6 mM (NH4)SO4;
2 mM MgCl2; 0.17 mg/ml BSA) and 0.5 U AmpliTaq DNA
polymerase (Applied Biosystems). Cycling conditions were:
90 s at 948C, 24  (30 s at 948C; 30 s at 658C; 90 s at 728C)
and 10 min at 728C. For HdhQ150 mice, the amplification
reaction was as for genotyping (above) with a FAM-labelled
reverse MHD18 primer. All instruments and materials were
obtained from Applied Biosystems unless indicated. The
FAM-tagged PCR product (1 ml) together with MegaBAC
E
TM
ET900 (Amersham Bioscience) internal size standard
(0.04 ml) were denatured at 948C, 5 min in 9 ml of HiDi-
formamide and analyzed using an ABI3730 sequencer. Data
analysis was performed using plate manager application Gen-
eMapper v5.2- 3730XL.
Antibodies
MW8 (26) is a monoclonal antibody that was raised against
the peptide AEEPLHRP at the C-terminus of exon 1. MW1
(26) and 3B5H10 (27) (Sigma) are both monoclonal antibodies
that detect expanded polyQ tracts, MW1 was raised against
polyQ and 3B5H10 (27) was raised against an N-terminal
171 amino acid fragment of huntingtin with 65Q. S830 is a
sheep polyclonal antibody that was raised against an exon 1
Htt protein with 53Q (23).
Seprion ligand ELISA
Brains were dissected, snap-frozen in liquid N2 and stored at
2808C until required. A 2.5% lysate was prepared in
ice-cold RIPA buffer (50 mM Tris–HCl pH 8.0; 120 mM
NaCl; 1% Igepal; 3.125% sodium deoxycholate; 0.01%
SDS; 1 mM b-mercaptoethanol; 1 mM PMSF; 1 mM DTT; pro-
tease inhibitor cocktail (Roche)) by ribolysing for 3  30 s in
Lysing matrix tubes (Lysing matrix D; MP Biomedicals).
Samples were stored on ice for 5 min and used immediately
or frozen on dry ice, stored at 2808C and used within 24 h.
Homogenate (15 ml) was mixed with 3 ml 10% SDS, diluted
to 80 ml with water, and then made up to 100 ml with 5
capture buffer (Microsens Biotechnologies). This was trans-
ferred to the well of a Seprion ligand-coated ELISA plate,
and incubated with shaking for 1 h at room temperature
(RT). After removal of the lysate, the well was washed 5
in PBS-T (PBS; 0.1% Tween) and 100 ml S830 primary anti-
body (diluted 1:2000 in conjugate buffer (150 mM NaCl; 4%
BSA (98% electrophoretic grade); 1% non-fat dried milk;
0.1% Tween 20 in PBS) was added and incubated with
shaking for 1 h at RT. After five washes with PBS-T, 100 ml
horse radish peroxidase (HRP)-conjugated rabbit anti-goat
secondary antibody (DAKO) (1:2000 in conjugation buffer)
was added and incubated with shaking for 45 min at RT.
After washing five times with PBS-T, 100 ml of TMB sub-
strate (SerTec) at RT was added and incubated in the dark
(wrapped in foil) at RT for 30 min. Reactions were terminated
by the addition of 100 ml 0.5 M HCl and the absorption at
450 nm was measured using a plate reader (Biorad).
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Seprion ligand bead capture
A 10% brain homogenate was prepared by ribolysing in
ice-cold RIPA buffer for 3  30 s in Lysing matrix tubes
(Lysing matrix D; MP Biomedicals). Seprion-coated magnetic
beads of 100 ml (Microsens Biotechnologies) was transferred
to an Eppendorf tube on a magnetic particle concentrator
(Dynal MPC-s). The supernatant was removed and replaced
with 100 ml of ultrapure water prior to use in the assay.
About 50–100 ml of homogenate was diluted to 700 ml with
water and made up to 1 ml with 200 ml 5 capture buffer
(Microsens Technologies) and 100 ml of coated beads. The
tube was shaken on a Vibrax shaker (VXR basic IKA
Vibrax) for 1 h at 1000 mot/min at RT, transferred to the mag-
netic concentrator and the supernatant removed. The beads
were washed with 500 ml of 1 capture buffer followed by
2  1 ml of TBS (Microsens Biotechnologies) and 1 
300 ml of TBS. Traces of TBS were removed by pipette
after quickly spinning in a microfuge. The captured material
was eluted by mixing with 20 ml of 0.75% SDS and heating
at 1008C for 5 min in a heating block.
Western blotting
For immunoblotting,10 ml of the eluted material from the bead
capture assay was mixed with 5 ml of 2 Laemmli loading
buffer, denatured at 1008C for 10 min and loaded on the
10% SDS–PAGE gel. After electrophoresis, proteins were
transferred to nitrocellulose membranes (Schleicher and
Schuell) in 25 mM Tris–HCl, 192 mM glycine, 20% v/v metha-
nol. Membranes were blocked for overnight in PBS (10 mM
Na2HPO4, 2 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl,
(pH7.4)) containing 4% non-fat dried milk at 48C, washed
with PBS-T (PBS with 0.1% tween-20), and incubated for
1 h with the primary antibody (in PBS-T containing 0.5%
non-fat dried milk). Blots were washed with PBS-T, probed
with HRP-linked secondary antibodies (in PBS with 0.5%
non-fat dried milk) for 1 h and washed again with
PBS-T. Bound antibodies were visualized using the enhanced
chemiluminescence detection system according to the manu-
facturer’s instructions (GE Healthcare). Primary antibodies
and dilutions were: S830 (23) (sheep polyclonal Ab 1:750),
MW1 (26) (monoclonal Ab 1:1000), MW8 (26) (monoclonal
Ab 1:750), 3B5H10 (Sigma) (monoclonal Ab 1:5000),
HRP-conjugated secondary antibodies were as follows:
rabbit anti-mouse (Dako 1:5000), rabbit anti-goat (Dako,
1:3000). All incubations were performed at RT.
Electron microscopy
For immune-labelling, 20 ml eluted material from the bead
capture assay was dried at 958C in a heating block and resus-
pended in 9 ml ultrapure water. Three microlitres were trans-
ferred to a freshly glow-discharged Formvar/carbon-coated
grid and incubated at RT for 1 min. Excess solution was
removed and the grid allowed to air-dry for 5 min. Grids
were rinsed briefly in PBS and transferred to blocking solution
(0.1% BSA-C
TM
(Aurion) in PBS) for 15 min. This was fol-
lowed by incubation with primary antibody diluted in blocking
solution for 1 h. Antibody dilutions were: MW1 1:100; MW8
1:100; 3B5H10 1:5000. The grids were washed six to eight
times in a drop of blocking solution (2 min/drop) and trans-
ferred to secondary antibody conjugated with 10 nm colloidal
gold particles (BB International) diluted 1:200 in blocking sol-
ution for 1 h. The grids were washed as above, followed by
two rinses in a drop of ultrapure water (1 min/drop) and air-
dried for 3 min. Negative staining was performed by adding
3 ml of 1% uranyl acetate for 45 s, excess stain was
removed with hardened filter paper and grids allowed to
air-dry. Images were taken with a transmission electron micro-
scope (Tecnai 12 Biotwin; FEI) at 120 kV. For electron tom-
ography, tilt series were acquired fully automatically using
FEI proprietary software running on an FEI Tecnai G2 trans-
mission electron microscope operating at 200 kV. Digital
images of the structures of interest were recorded at 10 tilt
intervals from 2650 to þ650 on a 2K Gatan Ultrascan
CCD camera.
Atomic force microscopy
Aggregates were captured by Seprion beads and eluted with
20 ml 100 mM KCl. From each preparation 2.5 ml was depos-
ited on freshly cleaved mica plate (Ted Pella Inc, Redding,
CA) and incubated for 1 min at RT. The captured material
was washed with 200 ml of ultrapure water and dried under
a gentle stream of air. Exon 1 Htt recombinant proteins (33)
were prepared as described in (43) and incubated at a concen-
tration of 20 mM for 1 h. Each deposition was imaged ex situ
using a MFP3D scanning probe microscope (Asylum
Research, Santa Barbara, CA, USA). Images were taken
with silicon cantilevers with a nominal spring constant of
40 N/m and resonance frequency of approximately 300 kHz.
Typical imaging parameters were: drive amplitude 150–
500 mV with set points of 0.7–0.8 V, scan frequencies of
2–4 Hz, image resolution 512  512 points, and scan size of
3 mm. All the experiments were performed in duplicates.
Several images were obtained from separate locations across
the mica surfaces to ensure reproducibility. Quantitative
analysis of AFM images: size analysis of aggregates observed
by AFM was performed using routines written in MATLAB
(MathWorks, Natick, MA, USA) equipped with the image-
processing toolbox. Individual aggregates in an AFM image
are automatically located and their volumes and heights and
other geometrical characteristics are measured, facilitating
quick analysis of thousands of individual aggregates. Contri-
butions owing to the finite shape and size of the tip were com-
pensated for, based on geometrical simulations as described
previously (44).
Statistical analysis
Statistical analysis was performed by Student’s t-test and
one-way ANOVA using SPSS.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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